⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1909467 | 0.88 | SYK (0.33) | — | |
| SCHEMBL554118 | 0.73 | LCK (0.39) | — | |
| SCHEMBL17221418 | 0.63 | SYK (0.33) | — | |
| SCHEMBL29958325 | 0.63 | SYK (0.33) | — | |
| SCHEMBL21027805 | 0.63 | PAX8 (0.33) | — | |
| SCHEMBL30176186 | 0.62 | SYK (0.37) | — | |
| SCHEMBL20741559 | 0.62 | SYK (0.37) | — | |
| SCHEMBL17242438 | 0.61 | DPP4 (0.32) | — | |
| SCHEMBL480926 | 0.61 | AOC3 (0.36) | — | |
| SCHEMBL1909270 | 0.61 | ALDH1A1 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290485-B2 | N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| EP-2601189-B1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2015-04-15 | — | — | EP | disclosed |
| EP-2601189-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | Novartis AG (CH) | 2013-06-12 | — | — | EP | disclosed |
| US-20120035168-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES | NOVARTIS AG (CH) | 2012-02-09 | — | — | US | disclosed |
| WO-2012017020-A1 | N-((6-AMINO-PYRIDIN-3-YL)METHYL)-HETEROARYL-CARBOXAMIDES AS INHIBITORS OF PLASMA KALLIKREIN | NOVARTIS AG (CH) | 2012-02-09 | — | — | WO | disclosed |